Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Phase 1b, Open-Label Trial to Evaluate Safety and Tolerability of a Novel Somatic Cell Therapy, AmnioPul-02,in Subjects With Confirmed COVID-19 or Other Viral Lower Respiratory Tract Infections

NCT05348772 is registered in ClinicalTrials.gov with Amniotics AB as lead sponsor.

NCT NCT05348772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Phase 1b, Open-Label Trial to Evaluate Safety and Tolerability of a Novel Somatic Cell Therapy, AmnioPul-02,in Subjects With Confirmed COVID-19 or Other Viral Lower Respiratory Tract Infections
Lead sponsor
Amniotics AB
Phase
Phase 1
Overall status
Completed
Start date
October 10, 2022
Completion date
February 9, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19